Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAVA GROUP, INC.CAVA · Entity 756 | Director | June 22, 2026 | June 24, 2026 |
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | Director | June 03, 2026 | June 04, 2026 |
| WW INTERNATIONAL, INC.WTW · Entity 6479 | Director | January 02, 2019 | January 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAVA GROUP, INC.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,955 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 1,881 · Balance 19,955 F1: Reflects a grant of restricted stock units ("RSUs"), which vest in full on the earlier of (i) June 22, 2027 and (ii) the business day before the date of the next annual meeting of the stockholders of CAVA Group Inc. (the "Issuer"), subject to the reporting person's continued service through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share upon settlement. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs"), which vest in full on the earlier of (i) June 22, 2027 and (ii) the business day before the date of the next annual meeting of the stockholders of CAVA Group Inc. (the "Issuer"), subject to the reporting person's continued service through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share upon settlement.
F2: Includes unvested RSUs.
LEXICON PHARMACEUTICALS, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 374,486 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Exercise / conversion · Acquired 89,312 · Balance 374,486 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Exercise / conversion · Disposed 89,312 · Balance 0 F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2: Each restricted stock unit represents a contingent right to receive one share of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
WW INTERNATIONAL, INC.
Report date January 02, 2019 · Filed January 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,484 |
Reported balance
After 2019-01-02 transaction · row 1
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 453 · Balance 47,484 F1: The shares listed represent shares of Common Stock subject to transfer restrictions. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares listed represent shares of Common Stock subject to transfer restrictions.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Buffalo Pet Products, Inc.
Report date April 24, 2018 · Filed April 24, 2018
Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-24 transaction · row 1
1 source rowRow 1 · 2018-04-24 · Disposition to issuer · Disposed 10,569 · Balance 0 F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 20:01 UTC | CAVA GROUP, INC. CAVA · Entity 756 | GrantCommon Stock | 1,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-045156 · wk-form4_1782331276.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,955 F1 · kind: Reflects a grant of restricted stock units ("RSUs"), which vest in full on the earlier of (i) June 22, 2027 and (ii) the business day before the date of the next annual meeting of the stockholders of CAVA Group Inc. (the "Issuer"), subject to the reporting person's continued service through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share upon settlement. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 89,312 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000103 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 89,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:10 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 89,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000103 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:59 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 43,478 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001062822-26-000092 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,478 Underlying: Common Stock · 43,478 shares Expires 2036-05-01 F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:59 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 35,714 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062822-26-000092 · form4.xml · derivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,714 Underlying: Common Stock · 35,714 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 21:23 UTC | CAVA GROUP, INC. CAVA · Entity 756 | GrantCommon Stock | 1,767 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032885 · wk-form4_1750800194.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,074 F1 · kind: Reflects a grant of restricted stock units ("RSU"), which vest in full on the earlier of (i) June 20, 2026 and (ii) the business day before the date of the next annual meeting of the stockholders of CAVA Group Inc. (the "Issuer"), subject to the reporting person's continued service through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share upon settlement. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 20:21 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 89,312 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-016461 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,312 Underlying: Common Stock · 89,312 shares Expires not disclosed F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| June 03, 2025 Filed Jun 3, 2025 20:21 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 103,806 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0001127602-25-016461 · form4.xml · derivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,806 Underlying: Common Stock · 103,806 shares Expires 2035-06-03 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| May 13, 2025 Filed May 13, 2025 21:49 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 36,810 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014140 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 13, 2025 Filed May 13, 2025 21:49 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 36,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014140 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:05 UTC | CAVA GROUP, INC. CAVA · Entity 756 | GrantCommon Stock | 1,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-029569 · wk-form4_1719259522.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,307 F1 · kind: Reflects a grant of restricted stock units ("RSU"), which vest in full on the earlier of (i) June 20, 2025 and (ii) the business day before the date of the next annual meeting of the stockholders of CAVA Group Inc. (the "Issuer"), subject to the reporting person's continued service through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share upon settlement. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| May 13, 2024 Filed May 13, 2024 20:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 36,810 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-015076 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,810 Underlying: Common Stock · 36,810 shares Expires not disclosed F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 13, 2024 Filed May 13, 2024 20:00 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 44,906 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001127602-24-015076 · form4.xml · derivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,906 Underlying: Common Stock · 44,906 shares Expires 2034-05-13 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 28, 2024 Filed Apr 29, 2024 20:16 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 8,032 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013553 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,032 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 28, 2024 Filed Apr 29, 2024 20:16 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 8,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013553 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 21:00 UTC | CAVA GROUP, INC. CAVA · Entity 756 | PurchaseCommon Stock | 10,000 | $33.18 | $331,800.00 |
DisclosureSEC source: 0001628280-23-039763 · wk-form4_1700600447.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $33.13 to $33.21 per share, inclusive. The reporting person undertakes to provide to CAVA Group, Inc., any security holder of CAVA Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: Includes unvested restricted stock units. Read SEC document |
| November 13, 2023 Filed Nov 14, 2023 21:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 200,000 | $1.01 | $201,520.00 |
DisclosureSEC source: 0001127602-23-027360 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,332 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.9858 to $1.0400 per share. The price reported above reflects the weighted average purchase price of such trades. Mr. Amouyal hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which this transaction was effected. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:36 UTC | CAVA GROUP, INC. CAVA · Entity 756 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-023150 · wk-form4_1687466203.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · kind: Reflects a grant of restricted stock units ("RSU"), which vest in full on the earlier of (i) June 14, 2024 and (ii) the business day before the date of the next annual meeting of the stockholders of CAVA Group, Inc. (the "Issuer"), subject to the reporting person's continued service through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share upon settlement. F2 · balance_after: Includes unvested RSUs. Read SEC document |
| May 21, 2023 Filed May 22, 2023 20:01 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 9,302 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016428 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,302 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 21, 2023 Filed May 22, 2023 20:01 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 9,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016428 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 20:21 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 12,658 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001127602-23-013780 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,658 Underlying: Common Stock · 12,658 shares Expires 2033-04-28 F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 20:21 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 8,032 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-013780 · form4.xml · derivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,032 Underlying: Common Stock · 8,032 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 21, 2022 Filed May 23, 2022 20:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 9,302 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015365 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,302 Underlying: Common Stock · 9,302 shares Expires not disclosed F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 21, 2022 Filed May 23, 2022 20:12 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 14,402 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001127602-22-015365 · form4.xml · derivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,402 Underlying: Common Stock · 14,402 shares Expires 2032-05-21 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 30, 2022 Filed May 2, 2022 20:11 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 4,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012824 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 30, 2022 Filed May 2, 2022 20:11 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 4,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012824 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2021 Filed May 3, 2021 21:02 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 6,475 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-21-014960 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,475 Underlying: Common Stock · 6,475 shares Expires 2031-04-30 F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 30, 2021 Filed May 3, 2021 21:02 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 4,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014960 · form4.xml · derivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,024 Underlying: Common Stock · 4,024 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 24, 2021 Filed Apr 27, 2021 20:45 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 10,638 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014517 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 24, 2021 Filed Apr 27, 2021 20:45 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 10,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014517 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2020 Filed Apr 27, 2020 20:43 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 3,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-014560 · form4.xml · derivative · entry 4 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 26, 2020 Filed Apr 27, 2020 20:43 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 3,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-014560 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 20:43 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 10,638 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-014560 · form4.xml · derivative · entry 3 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,638 Underlying: Common Stock · 10,638 shares Expires not disclosed F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 20:43 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 18,115 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001127602-20-014560 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,115 Underlying: Common Stock · 18,115 shares Expires 2030-04-24 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:07 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 3,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-016496 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,466 Underlying: Common Stock · 3,466 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:07 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 6,519 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001127602-19-016496 · form4.xml · derivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,519 Underlying: Common Stock · 6,519 shares Expires 2029-04-26 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:09 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 453 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001885 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,484 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:10 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-053770 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,031 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 20:54 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | SaleCommon Stock | 7,500 | $75.59 | $566,890.50 |
DisclosureSEC source: 0001209191-18-049233 · doc4.xml · nonDerivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,769 F1 · price: This transaction was executed in multiple trades at prices ranging from $75.58 to $75.61, inclusive. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 20:54 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-049233 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,269 Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:14 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-041575 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,769 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| April 27, 2018 Filed Apr 27, 2018 21:35 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 2,857 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001127602-18-015439 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Common Stock · 2,857 shares Expires 2028-04-27 F1 · derivative.exercise_date: Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant. Read SEC document |
| April 27, 2018 Filed Apr 27, 2018 21:35 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantCommon Stock | 2,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-015439 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,902 Read SEC document |
| April 24, 2018 Filed Apr 24, 2018 20:54 UTC | Blue Buffalo Pet Products, Inc. BUFF · Entity 167336 | Disposition to issuerCommon Stock | 10,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-010667 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 20:25 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 295 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-023647 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,582 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:15 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001918 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,287 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:46 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-055897 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,897 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 20:03 UTC | WW INTERNATIONAL, INC. WTW · Entity 6479 | GrantCommon Stock | 569 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043968 · doc4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,462 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| April 28, 2017 Filed May 1, 2017 20:47 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 2,857 | $0.00 Strike: $15.61 | $0.00 |
DisclosureSEC source: 0001127602-17-016054 · form4.xml · derivative · entry 2 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Common Stock · 2,857 shares Expires 2027-04-28 F1 · derivative.exercise_date: Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant. Read SEC document |
| April 28, 2017 Filed May 1, 2017 20:47 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantCommon Stock | 1,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016054 · form4.xml · nonDerivative · entry 1 Amouyal Philippe · CIK 0001376854 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,338 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.